Lizhi Lv

657 total citations
42 papers, 487 citations indexed

About

Lizhi Lv is a scholar working on Molecular Biology, Cancer Research and Surgery. According to data from OpenAlex, Lizhi Lv has authored 42 papers receiving a total of 487 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 18 papers in Cancer Research and 12 papers in Surgery. Recurrent topics in Lizhi Lv's work include MicroRNA in disease regulation (9 papers), Cancer-related molecular mechanisms research (9 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Lizhi Lv is often cited by papers focused on MicroRNA in disease regulation (9 papers), Cancer-related molecular mechanisms research (9 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Lizhi Lv collaborates with scholars based in China and Hong Kong. Lizhi Lv's co-authors include Yi Jiang, Yi Jiang, Deng‐Fu Guo, Qing Wei, Fang Yang, Fengfeng Xu, Yi Cao, Fu-Xing Zhang, Fang Yang and Jianwei Chen and has published in prestigious journals such as PLoS ONE, Scientific Reports and Archives of Biochemistry and Biophysics.

In The Last Decade

Lizhi Lv

37 papers receiving 485 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lizhi Lv China	13	235	150	100	81	80	42	487
Yihu Zheng China	12	297 1.3×	191 1.3×	82 0.8×	70 0.9×	41 0.5×	30	544
Vera P. Leoni Italy	17	472 2.0×	165 1.1×	88 0.9×	100 1.2×	52 0.7×	30	723
Omar Motiño Spain	16	253 1.1×	102 0.7×	55 0.6×	168 2.1×	70 0.9×	31	561
Lifang Wu China	14	189 0.8×	108 0.7×	42 0.4×	55 0.7×	58 0.7×	23	424
Rui Yan China	11	224 1.0×	104 0.7×	38 0.4×	56 0.7×	29 0.4×	36	446
Jingjing Wu China	14	309 1.3×	112 0.7×	55 0.6×	55 0.7×	32 0.4×	27	535
Peng Meng China	13	383 1.6×	171 1.1×	140 1.4×	92 1.1×	22 0.3×	22	649
Henglei Lu China	12	194 0.8×	110 0.7×	68 0.7×	110 1.4×	21 0.3×	20	429
Marilena Castelli Italy	14	229 1.0×	88 0.6×	83 0.8×	43 0.5×	30 0.4×	23	413
Nong Li China	12	186 0.8×	95 0.6×	55 0.6×	123 1.5×	37 0.5×	25	411

Countries citing papers authored by Lizhi Lv

Since Specialization

Citations

This map shows the geographic impact of Lizhi Lv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lizhi Lv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lizhi Lv more than expected).

Fields of papers citing papers by Lizhi Lv

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lizhi Lv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lizhi Lv. The network helps show where Lizhi Lv may publish in the future.

Co-authorship network of co-authors of Lizhi Lv

This figure shows the co-authorship network connecting the top 25 collaborators of Lizhi Lv. A scholar is included among the top collaborators of Lizhi Lv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lizhi Lv. Lizhi Lv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lv, Lizhi, et al.. (2025). Discovery of microplastics and nanoplastics in pediatric myocardium and blood. Environmental Technology & Innovation. 40. 104371–104371.

Lv, Lizhi, et al.. (2025). Uricolysis by Arthrobacter globiformis uricase: structural basis for its catalytic activity and thermostability. Acta Pharmacologica Sinica. 46(12). 3376–3385.

Lv, Lizhi, et al.. (2024). Impact of pulmonary artery intramural hematoma on patients with acute type A aortic dissection. European Radiology. 34(11). 7275–7284.

Li, Dong, et al.. (2023). Bioinformatics analysis and experimental validation of a novel autophagy-related signature relevant to immune infiltration for recurrence prediction after curative hepatectomy. Aging. 15(7). 2610–2630. 4 indexed citations

Lv, Lizhi. (2023). The urinary RNA atlas of patients with chronic kidney disease. Scientific Reports. 13(1). 19084–19084. 3 indexed citations

Liu, Jianyong, et al.. (2023). Pre- to postoperative alpha-fetoprotein ratio-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma. Frontiers in Oncology. 13. 1134933–1134933. 2 indexed citations

Chen, Minyong, et al.. (2023). SNRPD1 inhibition suppresses the proliferation of hepatocellular carcinoma and promotes autophagy through the PI3K/AKT/mTOR/4EBP1 pathway. Archives of Biochemistry and Biophysics. 743. 109661–109661. 6 indexed citations

Chen, Zhijian, et al.. (2023). Upregulation of lncRNA PTOV1‐AS1 in hepatocellular carcinoma contributes to disease progression and sorafenib resistance through regulating miR‐505. Journal of Biochemical and Molecular Toxicology. 37(10). e23437–e23437. 7 indexed citations

Huang, Xinghua, et al.. (2022). Immune Analysis and Small Molecule Drug Prediction of Hepatocellular Carcinoma Based on Single Sample Gene Set Enrichment Analysis. Cell Biochemistry and Biophysics. 80(2). 427–434. 7 indexed citations

10.

Chen, Can, et al.. (2021). miR-369-3p Serves as Prognostic Factor and Regulates Cancer Progression of Hepatocellular Carcinoma. Personalized Medicine. 18(4). 375–388. 3 indexed citations

11.

Gao, Yanjun, Yixuan Ye, Jing Wang, et al.. (2020). Effects of titanium dioxide nanoparticles on nutrient absorption and metabolism in rats: distinguishing the susceptibility of amino acids, metal elements, and glucose. Nanotoxicology. 14(10). 1301–1323. 20 indexed citations

12.

Zhang, Kun, Lizhi Lv, Yaping Dong, et al.. (2019). Prognostic value and oncogene function of heterogeneous nuclear ribonucleoprotein A1 overexpression in HBV-related hepatocellular carcinoma. International Journal of Biological Macromolecules. 129. 140–151. 18 indexed citations

13.

Jiang, Yi, et al.. (2019). Suppression of microRNA‑27a protects against liver ischemia/reperfusion injury by targeting PPARγ and inhibiting endoplasmic reticulum stress. Molecular Medicine Reports. 20(5). 4003–4012. 9 indexed citations

14.

Cao, Yi, et al.. (2017). Prognostic Value of Ki67 Expression for Patients with Surgically Resected Hepatocellular Carcinoma: Perspectives from a High Incidence Area. Clinical Laboratory. 63(02/2017). 355–364. 12 indexed citations

15.

Yang, Fang, et al.. (2017). Elevated FOXC2 Expression Promotes Invasion of HCC Cell Lines and is Associated with Poor Prognosis in Hepatocellular Carcinoma. Cellular Physiology and Biochemistry. 44(1). 99–109. 10 indexed citations

16.

Cao, Yi, et al.. (2016). Prognostic Value of Pre-Operative Platelet to Lymphocyte Ratio in Patients with Resected Primary Hepatocellular Carcinoma. Clinical Laboratory. 62(11/2016). 2191–2196. 11 indexed citations

17.

Lv, Lizhi, et al.. (2016). Dihydromyricetin protects against liver ischemia/reperfusion induced apoptosis via activation of FOXO3a-mediated autophagy. Oncotarget. 7(47). 76508–76522. 43 indexed citations

18.

Yang, Fang, et al.. (2014). Rho GDP Dissociation Inhibitor Beta Promotes Cell Proliferation and Invasion by Modulating the AKT Pathway in Hepatocellular Carcinoma. DNA and Cell Biology. 33(11). 781–786. 14 indexed citations

19.

Lv, Lizhi, et al.. (2013). Mitofusin 2 Protects Hepatocyte Mitochondrial Function from Damage Induced by GCDCA. PLoS ONE. 8(6). e65455–e65455. 22 indexed citations

20.

Bi, Jiong, Ailin Guo, Jiang F. Zhong, et al.. (2010). Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: a study on tissue microarrays. Neoplasma. 57(3). 191–197. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact